Navigation Links
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Date:12/11/2007

view your medical history and tell your doctor if you:

-- Have heart failure or other heart problems

-- Have liver problems or liver disease

-- Are pregnant or are nursing

Women taking Avandia should know that Avandia may increase the risk of pregnancy.

More fractures have been observed in women taking Avandia.

For more information about Avandia, please see Patient Information. For further information on Avandia, please see full Prescribing Information.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the company's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report 2006.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
9. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  CytomX, a biotechnology ... cancer, today announced the appointments of Bob ... Cynthia Ladd as senior vice president and ... chief financial officer of Onyx Pharmaceuticals, an Amgen ... consultant and legal counsel to several leading biotech ...
(Date:5/27/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... of the Company,s Series A and Series A-1 ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March 31, ... Series A Preferred Stock and Series A-1 Preferred ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACTâ„¢, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... , May 26, 2015   Intrexon Corporation (NYSE: ... that Gregory Frost , Ph.D., Senior Vice President and ... 2015 Global Healthcare Conference on Wednesday, June 3 rd , ... New York City . About ... is Powering the Bioindustrial Revolution with Better DNA ™ ...
Breaking Biology Technology:CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
... Business Development Efforts, SALT LAKE CITY, Sept. ... the development of molecular diagnostic and motion preserving,technologies ... Joe Ross has,joined the executive management team as ... In this new role, Ross will oversee Axial ...
... 14% from the, prior year,s third quarter - Earnings per share ... - Operating cash flow of $23 million, (Year-to-date operating cash flow of ... ... Martek Biosciences,Corporation (Nasdaq: MATK ) today announced its financial results ...
... and National Development in Taiwan, 1950-2000, Celebrates ... Editor of a Comprehensive History of ... Dialogue on a National Health Care System ... Worth Studying, NEW YORK, Sept. 4 ...
Cached Biology Technology:Axial Biotech appoints new Vice President of Strategic Initiatives 2Martek Announces Third Quarter 2008 Financial Results 2Martek Announces Third Quarter 2008 Financial Results 3Martek Announces Third Quarter 2008 Financial Results 4Martek Announces Third Quarter 2008 Financial Results 5Martek Announces Third Quarter 2008 Financial Results 6Martek Announces Third Quarter 2008 Financial Results 7Martek Announces Third Quarter 2008 Financial Results 8Martek Announces Third Quarter 2008 Financial Results 9Martek Announces Third Quarter 2008 Financial Results 10ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan 2ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan 3
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
(Date:5/26/2015)... , May 26, 2015 ... the addition of the "Saudi Arabia Biometric ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... is projected to grow at over ... growth is attributed to the surging demand for ...
(Date:5/25/2015)... , May 25, 2015  Australia,s market for wearable ... although 2014 saw the advent of several trials and ... April 2015 is expected to ignite interest in wearables ... Australia . This in turn will ... and drive new partnerships amongst vendors and distributors. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... pollution and heavy fishingare adding insult to injury in ... by the Wildlife Conservation Society and the University of ... found that pollution and overfishing on reef systems have ... wormsthat further degrade corals, a discovery that underlines the ...
... at UCLA,s Jonsson Cancer Center found that the children ... having retinoblastoma, a malignant tumor of the retina which ... which focused on babies born in California, also found ... for retinoblastoma, as were children born to women with ...
... are overweight or obese can encounter a host of health ... children grow and develop, at least initially. In a ... a team led by a University of Iowa researcher compared ... obese mothers with those born to normal-weight mothers. ...
Cached Biology News:Microbes, sponges, and worms add to coral reef woes 2Microbes, sponges, and worms add to coral reef woes 3US-born Latinas at great risk of having babies with retinoblastoma 2Infants of overweight mothers grow more slowly 2Infants of overweight mothers grow more slowly 3
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
... recombinant IFNA2. Immunogen: Human IFNA2 ... in E. coli. The biological activity was ... OMIM: 147562, GeneID: ... MA Code: ABV0P9DPB ...
... longer need to perform time consuming and inaccurate ... Surveyor, any found variants of the sample when ... in our mutation electropherogram as a sharp peak. ... analysis mode is over 99%, with sensitivity to ...
...
Biology Products: